Lifeward Ltd Stock Price, News & Analysis

Lifeward (Nasdaq: LFWD) announced on Nov 17, 2025 that a UnitedHealthcare Medicare Advantage plan issued a prior authorization for a ReWalk 7 Personal Exoskeleton. The approval follows CMS's 2024 reimbursement pathway for personal exoskeletons and is presented as a step toward broader payer adoption in the U.S.

The company said the UnitedHealthcare prior authorization may improve predictability in reimbursement, accelerate prior authorizations, and support scalable growth and cash flow dynamics for beneficiaries using ReWalk 7.

Lifeward (Nasdaq: LFWD) reported Q3 2025 results on Nov 14, 2025: revenue $6.2M (Q3 2024: $6.1M), net loss $3.2M or $0.20 per share, and cash used in operations $3.8M.

Key operational progress included a record quarter of ReWalk placements for Medicare beneficiaries, a 16% year‑over‑year reduction in quarterly cash burn, a 27% decline in quarterly non‑GAAP operating loss, and CE mark approval for ReWalk 7 enabling sales in Europe (~40% of exoskeleton sales). Lifeward also secured a $3.0M loan from Oramed and reaffirmed 2025 guidance of $24–$26M revenue and $12–$14M non‑GAAP net loss.

Lifeward (NASDAQ: LFWD) will release its third quarter 2025 financial results before markets open on Friday, November 14, 2025. A conference call and live webcast with CEO Mark Grant and CFO Almog Adar is scheduled for 8:30 a.m. EST the same day to discuss results.

Analysts and investors can join via toll-free U.S. dial-in 1-833-316-0561, international dial-in 1-412-317-0690, or regional numbers including Germany and Israel; participants should reference the "Lifeward Earnings Call" access code. The live webcast is available on the company website GoLifeward.com in Investors or at https://edge.media-server.com/mmc/p/522gfyx4, with an archived replay to follow on the site.

Lifeward (NASDAQ:LFWD) has achieved a significant milestone by receiving its first payment from a commercial Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton. The company has reported accelerated claim processing times, with approvals now taking just 30-60 days, compared to previously longer timelines.

Following CMS's 2024 establishment of a Medicare reimbursement pathway for personal exoskeletons, Lifeward has successfully streamlined the claims process. The majority of Medicare claims are now being approved upon initial submission, eliminating the need for lengthy appeals processes.

Lifeward (Nasdaq: LFWD) has received CE mark approval for its ReWalk 7 Personal Exoskeleton, enabling commercial sales in Europe. The seventh-generation device features advanced capabilities including cloud connectivity, push-button control, customizable walking speeds, and improved stairs/curbs navigation.

Europe represents 40% of Lifeward's exoskeleton sales, with Germany being the second-largest market globally. The company has established reimbursement agreements with major German insurers, including BARMER, covering approximately 45% of people with statutory health insurance in Germany.

Lifeward Ltd. (NASDAQ: LFWD) reported Q2 2025 financial results, showing mixed performance with revenue of $5.7 million, down 15% year-over-year but up 14% sequentially. The company achieved significant operational milestones, including FDA clearance for ReWalk 7 and record Medicare beneficiary placements.

Key financial metrics include a 43.9% gross margin and reduced quarterly cash burn to $3.9 million. The company reported a net loss of $6.6 million, or $0.58 per share. Lifeward appointed new leadership with Mark Grant as CEO and Almog Adar as CFO, while updating 2025 guidance to $24-26 million in revenue.

Notable achievements include successful transition to in-house manufacturing, expanded U.S. payer base, and positive Medicare rulings establishing ReWalk as "reasonable and necessary" for beneficiaries.

Lifeward (NASDAQ:LFWD), a medical technology company focused on transforming lives of people with physical limitations, has appointed Almog Adar as its new Chief Financial Officer. Adar, who previously served as the company's Vice President of Finance and Chief Accounting Officer, joined Lifeward in 2020 and has progressively taken on more senior roles within the finance organization.

Prior to Lifeward, Adar held controller positions at Infinya Recycling and Delta Galil Industries, and worked at Ernst & Young. He holds a Bachelor's degree in Accounting and Economics and is a Certified Public Accountant licensed by the Israeli Ministry of Justice.

Lifeward (NASDAQ: LFWD), a global leader in medical technology for people with physical limitations, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, before market open.

The company will host a conference call and webcast at 8:30 a.m. EDT featuring CEO Mark Grant and VP of Finance Almog Adar. Investors can access the call through various toll-free numbers in the U.S., Germany, and Israel, or view the webcast through the company's investor relations website.

Lifeward Ltd. (Nasdaq: LFWD), a medical technology company, has expanded its distribution partnership with SportsMed Products Ltd. to include the United Arab Emirates and the entire Gulf Cooperation Council (GCC) region. The expansion will be managed through SportsMed's Dubai-based entity, SportsMed Performance Trading LLC.

SportsMed Products has been the exclusive AlterG dealer in the UK and Ireland since 2015, with a track record of selling over 300 AlterG devices. The company has already established a demo zone in Dubai featuring the latest AlterG NEO+ system, demonstrating their commitment to the GCC market expansion.